Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity

Eloisi Caldas Lopes, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero, Malcolm A.S. Moore

Blood (2015) 126 (23): 1556.

https://doi.org/10.1182/blood.V126.23.1556.1556

Published: 2015

Journal Articles

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Joanna Szczepanek, Joanna Laskowska, Joanna Lewandowska-Bieniek, Andrzej Tretyn, Jan Styczynski, MD PhD

Blood (2014) 124 (21): 3802.

https://doi.org/10.1182/blood.V124.21.3802.3802

Published: 2014

Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2014) 124 (21): 2142.

https://doi.org/10.1182/blood.V124.21.2142.2142

Published: 2014

Journal Articles

Phosphoramide Mustard (PM) Population Pharmacokinetics to Estimate Inter-Individual Variability in Exposure and Identify Clinical Factors Associated with Variability in Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HCT) Patients

Kinjal Sanghavi, M Pharm, Anthony C. Wiseman, MD, Mark Kirstein, PharmD, Richard Brundage, PharmD PhD, Pamala A. Jacobson, PharmD

Blood (2014) 124 (21): 2478.

https://doi.org/10.1182/blood.V124.21.2478.2478

Published: 2014

Journal Articles

Pre-Clinical Evaluation of a Novel DNA Crosslinking Agent, Bo-1055 in B-Cell Lymphoma

Eloisi Caldas Lopes, Fabian Correa, Elizabeth Peguero, Srikanth R. Ambati, MBBS, MD, Jae Hung Shieh, Tsann Long SU, Malcolm A.S. Moore

Blood (2014) 124 (21): 5483.

https://doi.org/10.1182/blood.V124.21.5483.5483

Published: 2014

Journal Articles

Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT)

Anthony C. Wiseman, MD, Kinjal Sanghavi, M Pharm, Qing Cao, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD, John Rogosheske, PharmD, Andy Kurtzweil, PharmD, Daniel J. Weisdorf, MD, Pamala A. Jacobson, PharmD

Blood (2014) 124 (21): 1153.

https://doi.org/10.1182/blood.V124.21.1153.1153

Published: 2014

Journal Articles

Mechanisms and Prevention of Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Therapy

Takuro Nishikawa, MD PhD, Emiko Miyahara, PhD, Koichiro Kurauchi, MD, Erika Watanabe, PhC, Yasuhiro Okamoto, MD, Yoshifumi Kawano, MD PhD

Blood (2014) 124 (21): 5789.

https://doi.org/10.1182/blood.V124.21.5789.5789

Published: 2014

Journal Articles

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Marina Konopleva, MD, PhD, Damian R Handisides, Mary Ann Richie, RN, Juliana M Benito, PhD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Stewart Kroll, Michael Andreeff, MD, PhD, Hagop M Kantarjian, MD, Deborah A. Thomas, MD

Blood (2013) 122 (21): 3920.

https://doi.org/10.1182/blood.V122.21.3920.3920

Published: 2013

Journal Articles

Phosphoramide Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation

Anthony C. Wiseman, BS, Sanghavi Kinjal, BS, MS, Claudio Brunstein, MD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Qing Cao, MS, John Rogosheske, PharmD, Pamala A. Jacobson

Blood (2013) 122 (21): 5461.

https://doi.org/10.1182/blood.V122.21.5461.5461

Published: 2013

Journal Articles

Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302

Juliana M Benito, PhD, Volgin Y Andrei, Ye Chen, PhD, Lu Hongbo, Yuexi Shi, Teresa McQueen, Patrick A Zweidler-McKay, MD, PhD, Damian R Handisides, Charles Hart, Michael Andreeff, MD, PhD, Marina Konopleva, M.D., Ph.D.

Blood (2012) 120 (21): 1523.

https://doi.org/10.1182/blood.V120.21.1523.1523

Published: 2012

Journal Articles

Activity of the Hypoxia-Activated Prodrug, TH-302, in Human Acute Myeloid Leukemia Models

Scott Portwood, M.S., Deepika Lal, M.S., Yung-Chun Hsu, PhD, Rodrigo Vargas, M.S., Meir Wetzler, MD, Eunice S. Wang, MD

Blood (2012) 120 (21): 3611.

https://doi.org/10.1182/blood.V120.21.3611.3611

Published: 2012

Journal Articles

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Poonkuzhali Balasubramanian, Salamun Desire, M.Sc, John C Panetta, PhD, Kavitha M Lakshmi, MSc, Ezhilpavai Mohanan, M.Sc, Auro Viswabandya, Biju George, MD, Vikram Mathews, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 1941.

https://doi.org/10.1182/blood.V118.21.1941.1941

Published: 2011

Journal Articles

Clinicopathological Characteristics and Clinical Course of CD8 Expressing Primary Cutaneous Peripheral T-Cell Lymphomas (CTCL) - Retrospective Case Study

Deniz Peker, MD, Yizhou Zhang, Young Yu, Zhigang Zhao, Yafei Wang, Hongliang Yang, Frank Glass, Lynn Moscinski, MD, Lubomir Sokol, MD, PhD, Ling Zhang, MD

Blood (2011) 118 (21): 5213.

https://doi.org/10.1182/blood.V118.21.5213.5213

Published: 2011

Journal Articles

The Integrin Co-Activator Kindlin-2 Plays a Critical Role In Angiogenesis and Blood Vessel Integrity

Elzbieta Pluskota, PhD, James J Dowling, MD, Ph.D, Natalie Gordon, Jeffrey A Golden, MD, Dorota Szpak, XiaoXia Zhang, Carla Nestor, Yan-Qing Ma, Ph.D, Katarzyna Bialkowska, Ph.D., Tatiana Byzova, PhD, Edward F. Plow, PhD

Blood (2010) 116 (21): 4.

https://doi.org/10.1182/blood.V116.21.4.4

Published: 2010

Journal Articles

Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial.

Andrew R. Rezvani, MD, Jeannine S. McCune, PhD, Ami Batchelder, Barry E. Storer, PhD, George B. McDonald, MD, H. Joachim Deeg, MD

Blood (2009) 114 (22): 1175.

https://doi.org/10.1182/blood.V114.22.1175.1175

Published: 2009

Journal Articles

Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.

Marina Konopleva, MD, PhD, Juliana Benito, PhD, Yue-Xi Shi, Sergej Konoplev, MD, PhD, Steven M. Kornblau, MD, Olga Frolova, MD, PhD, Patrick A. Zweidler-McKay, MD, PhD, YiHua Qiu, MD, MS, William R. Wilson, PhD, Dario Campana, MD, PhD, Rodrigo Jacamo, PhD, Hongbo Lu, MMSC, Wendy Fang, MD, Gautam Borthakur, MD, Carlos E. Bueso-Ramos, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Michael Andreeff, MD, PhD

Blood (2009) 114 (22): 2040.

https://doi.org/10.1182/blood.V114.22.2040.2040

Published: 2009

Journal Articles

Colonel Mustard, with the rope, in the ballroom

Bruce M. Camitta

Blood (2006) 108 (3): 785.

https://doi.org/10.1182/blood-2006-05-022616

Published: 2006

Journal Articles

Isophosphoramide Mustard-Lysine (ZIO-201): Active Moiety of Ifosfamide (IFOS) without Kidney Toxicity.

Mary Taub, PhD, James E. Springate, MD, Emed Zaki, MD, Robert Struck, PhD

Blood (2005) 106 (11): 4727.

https://doi.org/10.1182/blood.V106.11.4727.4727

Published: 2005

Journal Articles

Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients.

Sandra J. Horning, MD, Richard T. Hoppe, MD, Ranjana Advani, MD, Roger Warnke, MD, David Baer, MD, Joseph Mason, MD, Saul A. Rosenberg, MD

Blood (2004) 104 (11): 308.

https://doi.org/10.1182/blood.V104.11.308.308

Published: 2004

Journal Articles

Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with β-Thalassemia Major.

Alok Srivastava, MD, Balasubramanian Poonkuzhali, Ph.D., Desire Salamun, M.Sc, Biju George, MD, DM, Vikram Mathews, MD, DM, Rajagopal Krishnamoorthy, Ph.D., Mammen Chandy, MD

Blood (2004) 104 (11): 1820.

https://doi.org/10.1182/blood.V104.11.1820.1820

Published: 2004

NARROW

Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Phosphoramide Mustard (PM) Population Pharmacokinetics to Estimate Inter-Individual Variability in Exposure and Identify Clinical Factors Associated with Variability in Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HCT) Patients

Pre-Clinical Evaluation of a Novel DNA Crosslinking Agent, Bo-1055 in B-Cell Lymphoma

Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT)

Mechanisms and Prevention of Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Therapy

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Phosphoramide Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation

Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302

Activity of the Hypoxia-Activated Prodrug, TH-302, in Human Acute Myeloid Leukemia Models

Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT

Clinicopathological Characteristics and Clinical Course of CD8 Expressing Primary Cutaneous Peripheral T-Cell Lymphomas (CTCL) - Retrospective Case Study

The Integrin Co-Activator Kindlin-2 Plays a Critical Role In Angiogenesis and Blood Vessel Integrity

Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial.

Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.

Colonel Mustard, with the rope, in the ballroom

Isophosphoramide Mustard-Lysine (ZIO-201): Active Moiety of Ifosfamide (IFOS) without Kidney Toxicity.

Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin’s Disease: Mature Data in Early and Advanced Stage Patients.

Cyclophosphamide Kinetics Influences Toxicity and Outcome of Bone Marrow Transplantation in Patients with β-Thalassemia Major.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only